Candice L. McAllister

Wilmington, DE ***** 302-***-****

www.linkedin.com/in/candicemcallister acxwtt@r.postjobfree.com

VERSATILE, CREATIVE IN VIVO PHARMACOLOGIST RESEARCHER MANAGER

Takes a resourceful, innovative approach to experimental design. Leverages broad experience in pharmaceutical industry, developing strategies employing current models and technologies to further novel therapy research and support preclinical development. Key contributor to several peer reviewed journal publications.

Results-oriented scientific professional with leadership experience, managing competing demands and deadlines to deliver quality results. Enjoy working with focused groups on cutting edge projects. Natural team-builder, adept at navigating complicated interpersonal situations, identifying professional development opportunities, and promoting top-performing staff. Areas of expertise include:

Aseptic Rodent Surgery Xenografts & Orthotopic Tumor Models Sterile Cell Culturing

In vivo Bioluminescence & Fluorescence Imaging IACUC Protocol

PROFESSIONAL EXPERIENCE

MORPHOTEK, INC., Exton, PA

Manager, Pharmacology 2010 – 2016

Developed, managed, and performed studies utilizing in vivo models in support of immuno-oncology target validation, drug candidate characterization, and preclinical studies. Directed daily operations of the barrier animal facility from a husbandry and regulatory perspective. Provided direct supervision to husbandry staff; oversaw staff training and performance management.

Created professional progression program for vivarium staff, wrote job descriptions for new roles, obtained HR approval for new process, and successfully developed direct reports to meet new criteria.

Collaborated with veterinarian staff to develop and implement functional SOPs and IACUC protocols and processes.

Implemented Study Log Software System: tracking animal inventory, completing IACUC census, and streamlining data collection.

Managed breeding and phenotype characterization for 12 transgenic mouse colonies by coordinating and collaborating between investigators and CROs. Coordinated with Finance to pay vendors and maintain project budgets.

Recognized variability in transgenic mouse models potentially due to sex-linked differences in immune system, resulting in optimization of in-house model development for immunotherapies.

Generated key results to support “go/no go” decisions for novel immunotherapies, antibody-drug conjugates, and immuno-oncology treatments by designing and executing experiments utilizing rodent oncology models.

Completed 6-month Scientist contract assignment with Astrix Technology Group (conducting experiments, accessing models, performing in vivo imaging, assisting in training staff), which led to full-time placement with Morphotek.

THE NEMOURS CENTER FOR CHILDHOOD CANCER RESEARCH, Wilmington, DE

In Vivo Core Director, Senior Research Assistant 2008 – 2010

Designed and conducted in vivo experiments. Supported translational research of childhood cancers. Key contributor for grant applications and publications. Delivered framework for successful launch of new Cancer Center’s in vivo laboratory.

In Vivo Core Director, Senior Research Assistant

Wrote IACUC protocols for investigators, implemented processes to bring immune-compromised mouse studies in-house, trained graduate students and post docs in animal handling and sample collection, resulting in a successful launch of the new Cancer Center.

Utilized xenografts, orthotopic tumor models, and transgenic mice to support translational research of childhood cancers and provide data for grant applications and publication.

Coordinated transgenic mouse breeding colony record management and genotyping, generating a smooth 2-fold expansion of in-house strains.

Planned and conducted in vitro experiments (focusing on biomarkers), exploring the relationship of cell signaling pathways with tumorigenicity and metastatic disease utilizing western blot, immuno-precipitation, and immuno-fluorescent technologies.

KELLY SCIENTIFIC, Radnor, PA

Scientist for Therakos (Contract) 2005 – 2007

Designed and conducted in vivo experiments. Supported proof of principle studies and explored new therapeutic indications for CELLEX Photopheresis Systems.

Supported exploration of new therapeutic indications by developing adoptive cell transfer studies utilizing extracorporeal photopheresis treated splenocytes in in vivo immunological models (GVHD, scleroderma), models of pulmonary inflammation, and metabolic disease.

Performed RNA extraction of tissue samples for chemokine analysis.

ADDITIONAL RELATED EXPERIENCE

GEO-CENTERS, Edgewood, MD

Scientist III, Toxicology

BRISTOL-MYERS SQUIB CO., Wilmington, DE

Research Scientist II, Inflammatory Biology

THE DUPONT PHARMACEUTICALS CO., Wilmington, DE

Sr. Staff Scientist

EDUCATION

Master of Science (MS), Drug Chemistry, University of Florida, Gainesville, FL

Master of Science (MS), Forensic Toxicology, University of Florida, Gainesville, FL

Bachelor of Science (BS), Animal Science, University of Delaware, Newark, DE

American Association of Laboratory Animal Science (AALAC), Laboratory Technician

MANUSCRIPTS

1. Grubb MF, Robinson CA, White SJ, Krauthauser CL, Shum L. Determination of a HIV protease inhibitor (DMP 450) in animal and human plasma by solid phase extraction and high performance liquid chromatography. J. Chrom. B 678: 303-308, 1996.

2. Kerr JS, Li H-Y, Wexler RS, Robinson AJ, Robinson CS, Boswell GA, Krauthauser C, Harlow PP. The characterization of potential novel warfarin analogs. Thrombosis Research 88 (2): 127-136, 1997.

3. Hall LA, Krauthauser CM, Wexler RS, Hollingshead M, Slee AM, Kerr JS. The hollow fiber assay: continued characterization with novel approaches. Anticancer Research 20: 903-912, 2000.

4. Krauthauser CM, Hall L-A, Wexler RS, Slee AM, Mitra J, Enders GH, Kerr JS. Regulation of Gene Expression and Cell Growth In Vivo by Tetracycline Using the Follow Fiber Assay. Anticancer Research. March/April issue 2001.

5. Ho SP, Scully MS, Krauthauser CM, Wexler EJ, Stow MD, Dinchuk JE, Kerr JS, Friedman PA. Antisense Oligonucleotides Selectively Regulate Aspartyl (-Hydroxylase and Its Truncated Protein Isoform in Vitro but Distribute Poorly into A549 Tumors in Vivo. JPET 302: 795-803, 2002.

6. Hall LA, Krauthauser CM, Wexler RS, Slee AM, Kerr JS. The hollow fiber assay. Methods Mol Med. 2003; 74: 545-66.

7. Hulet SW, Sommerville DR, Crosier RB, Dabisch PA, Miller DB, Benton BJ, Forster JS, Scotto JA, Jarvis JR, Krauthauser C, Muse WT, Reutter SA, Mioduszewski RJ, Thomson SA. Comparison of low-level sarin and cyclosarin vapor exposure on pupil size of the Gottingen minipig: effects of exposure concentration and duration. Inhal Toxicol. 2006 Feb; 18 (2): 143-53.

8. Das AM, Vaddi KG, Solomon KA, Krauthauser C, Jiang X, McIntyre KW, Yang XX, Wadman E, Welch P, Covington M, Graden D, Yeleswaram K, Trzaskos JM, Newton RC, Mandlekar S, Ko SS, Carter PH, Davies P. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation. J Pharmacol Exp Ther. 2006 Jul; 318 (1): 411-7. Epub 2006 Apr 13.

9. Lee SJ, Krauthauser C, Maduskuie V, Fawcett PT, Olson JM, Rajasekaran SA. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer. 2011 Apr 18; 11:144. doi: 10.1186/147*-****-**-***.

10. Lin J, Spidel JL, Maddage CJ, Rybinski KA, Kennedy RP, Krauthauser CL, Park YC, Albone EF, Jacob S, Goserud MT, Martinez BP, Chao Q, Zhou Y, Nicolaides NC, Kline JB, Grasso L. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity. Cancer Biol Ther. 2013 Aug 28; 14 (11).

Contact this candidate